Last $1.43 USD
Change Today +0.02 / 1.42%
Volume 31.2K
DCTH On Other Exchanges
Symbol
Exchange
DCTH is not on other exchanges.
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

delcath systems inc (DCTH) Snapshot

Open
$1.41
Previous Close
$1.41
Day High
$1.46
Day Low
$1.41
52 Week High
03/20/14 - $6.72
52 Week Low
11/6/14 - $1.32
Market Cap
13.9M
Average Volume 10 Days
43.1K
EPS TTM
$-1.04
Shares Outstanding
9.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DELCATH SYSTEMS INC (DCTH)

delcath systems inc (DCTH) Related Businessweek News

No Related Businessweek News Found

delcath systems inc (DCTH) Details

Delcath Systems, Inc. operates as a specialty pharmaceutical and medical device company focusing on the field of oncology in the United States and internationally. The company’s proprietary technology enables the administration of high-dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. It is primarily involved in the development of CHEMOSAT/Melphalan hepatic delivery system that administers concentrated regional chemotherapy to the liver. Delcath Systems, Inc. was founded in 1988 and is headquartered in New York, New York.

37 Employees
Last Reported Date: 03/12/14
Founded in 1988

delcath systems inc (DCTH) Top Compensated Officers

Interim Chief Executive Officer, Interim Pres...
Total Annual Compensation: $309.6K
Chief Compliance Officer, Executive Vice Pres...
Total Annual Compensation: $330.2K
Executive Vice President of Regulatory Affair...
Total Annual Compensation: $245.6K
Principal Accounting Officer, Vice President ...
Total Annual Compensation: $199.2K
Consultant
Total Annual Compensation: $333.6K
Compensation as of Fiscal Year 2013.

delcath systems inc (DCTH) Key Developments

Delcath Systems, Inc. Announces Treatment of First Patient in Phase 2 Trial of Melphalan Hepatic Delivery System in Primary Liver Cancer

Delcath Systems, Inc. announced that the first treatment has been performed in the company's Global Phase 2 Clinical Program for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC), or primary liver cancer. A team led by Prof. Dr. med. Thomas J. Vogl, Director of the Institute for Diagnostic and Interventional Radiology at Goethe University Hospital Frankfurt, Germany, treated its first case on November 5, 2014. The treating physicians reported that the patient was treated successfully. HCC is the most common primary cancer of the liver, with approximately 700,000 new cases diagnosed worldwide annually. Surgical removal is not possible for an estimated 80%-90% of primary liver cancer patients. In Europe, the Company's Phase 2 trial program will investigate the safety and efficacy of Melphalan/HDS treatment without sorafenib in patients with unresectable liver cancer confined to the liver, evaluate tumor response (objective response rate) as measured by modified Response Evaluation Criteria in Solid Tumor (mRECIST), and assess progression-free survival and safety. Additional analyses will be conducted to characterize the systemic exposure of melphalan administered by Melphalan/HDS, as well as assess patient-reported clinical outcomes, or quality-of-life. The Company's Phase 2 trial program is expected to include four to seven centers in Europe and the United States, and will seek to enroll approximately 30 patients.

Delcath Systems, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Delcath Systems, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenue of $217,000 against $72,000 a year ago. Loss from operations was $5,054,000 against $6,702,000 a year ago. Net loss was $4,558,000 or $0.48 per basic and diluted share against $6,206,000 or $1.15 per basic and diluted share a year ago. During the quarter, net cash used in operating activities was $4 million at the low end of its $4 million to $5 million quarterly cash utilization projection, the sixth consecutive quarter of meeting its projections. For the nine months period, the company reported total revenue of $778,000 against $152,000 a year ago. Loss from operations was $16,019,000 against $27,492,000 a year ago. Net loss was $14,436,000 or $1.54 per basic and diluted share against $25,533,000 or $4.35 per basic and diluted share a year ago. For the first nine months, net cash used in operating activities was $12.4 million, a 57% reduction compared to $28.9 million in the comparable period in 2013. The reduction was driven by the increase in NDA submission-related cost, the phasing out of the company’s medical science liaisons program, and improved organizational and operational efficiencies.

Delcath Systems, Inc. to Report Q3, 2014 Results on Nov 05, 2014

Delcath Systems, Inc. announced that they will report Q3, 2014 results at 4:30 PM, US Eastern Standard Time on Nov 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DCTH:US $1.43 USD +0.02

DCTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CTI BioPharma Corp $2.22 USD +0.05
Curis Inc $1.31 USD +0.05
Exact Sciences Corp $23.98 USD +1.49
Infinity Pharmaceuticals Inc $14.21 USD 0.00
Sirtex Medical Ltd A$26.10 AUD -0.45
View Industry Companies
 

Industry Analysis

DCTH

Industry Average

Valuation DCTH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.9x
Price/Book 0.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DELCATH SYSTEMS INC, please visit www.delcath.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.